Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug. It contains amlodipine, as the besilate, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist.[6] This combination is usually well tolerated and effective for the reduction of blood pressure.[7]
The combination was approved for medical use in the European Union in January 2007,[3] and in the United States in June 2007.[8]
The combination is also available with hydrochlorothiazide.[9][10] It was approved for medical use in the United States in April 2009,[11] and in the European Union in November 2009.[12][13][14] The combination of amlodipine/valsartan with hydrochlorothiazide is on the World Health Organization's List of Essential Medicines.[15]
References
- Amlodipine / valsartan (Exforge) Use During Pregnancy Drugs.com, 11 July 2019, retrieved 13 February 2020^
- Exforge- amlodipine besylate and valsartan tablet, film coated DailyMed, 12 June 2019, retrieved 12 February 2020^
- Exforge EPAR European Medicines Agency (EMA), 17 January 2007, retrieved 26 August 2024^
- Copalia EPAR European Medicines Agency (EMA), 16 January 2007, retrieved 26 August 2024^
- Dafiro EPAR European Medicines Agency (EMA), 16 January 2007, retrieved 26 August 2024^
- Valsartan Monograph for Professionals Drugs.com, American Society of Health-System Pharmacists, retrieved 3 March 2019^
- Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors Blood Pressure, September 2013^
- Drug Approval Package: Exforge (amlodipine and valsartan) NDA #021990 U.S. Food and Drug Administration (FDA), 3 October 2008, retrieved 19 September 2021^
- Exforge HCT- amlodipine valsartan and hydrochlorothiazide tablet, film coated DailyMed, retrieved 12 February 2020^
- Amlodipine, Valsartan, and Hydrochlorothiazide Drugs.com^
- Drug Approval Package: Exforge HCT (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets NDA #022314 U.S. Food and Drug Administration (FDA), 2 September 2009, retrieved 19 September 2021^
- Exforge HCT EPAR European Medicines Agency (EMA), 16 October 2009, retrieved 26 August 2024^
- Copalia HCT EPAR European Medicines Agency (EMA), 4 November 2009, retrieved 26 August 2024^
- Dafiro HCT EPAR European Medicines Agency (EMA), 4 November 2009, retrieved 26 August 2024^
- The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list World Health Organization, 2025^